Indolent lymphoma: Bendamustine, rituximab and acalabrutinib in Waldenstroms Macroglobulinemia (BRAWM).

MLA

Berinstein, N. L., et al. “Indolent Lymphoma: Bendamustine, Rituximab and Acalabrutinib in Waldenstroms Macroglobulinemia (BRAWM).” Hematological Oncology, vol. 41, June 2023, pp. 396–97. EBSCOhost, https://doi.org/10.1002/hon.3164_288.

APA

Berinstein, N. L., Roos, K., Klein, G., McClure, R., Forward, N., Shafey, M., Nikonova, A., MacDonald, D., Villa, D., Sandhu, I., Aljama, M., Larouche, J., & Mangoff, K. (2023). Indolent lymphoma: Bendamustine, rituximab and acalabrutinib in Waldenstroms Macroglobulinemia (BRAWM). Hematological Oncology, 41, 396–397. https://doi.org/10.1002/hon.3164_288

Chicago

Berinstein, N. L., K. Roos, G. Klein, R. McClure, N. Forward, M. Shafey, A. Nikonova, et al. 2023. “Indolent Lymphoma: Bendamustine, Rituximab and Acalabrutinib in Waldenstroms Macroglobulinemia (BRAWM).” Hematological Oncology 41 (June): 396–97. doi:10.1002/hon.3164_288.